Scientists in Britain begin clinical trial of vaccine from COVID-19 in humans. This was reported by the press service of Imperial College London on Tuesday, June 16. 300 volunteers aged 18 to 70 years were selected to participate in the study. They will be given two doses of the vaccine.. If the immune system of the subjects responds positively, the number of healthy volunteers will increase by another 6 thousand. Scientists say that the vaccine does not contain a weakened form of coronavirus, but consists of synthetic chains of its genetic code. It is also noted that previous animal trials of the drug have proven its safety and encouraging signs of effectiveness.. The development of the vaccine was carried out at the expense of 41 million pounds allocated by the UK government. This will be the first test of a new technology of self-enhancing RNA, which can revolutionize the development of vaccines and allow scientists to quickly respond to emerging diseases. “From a scientific point of view, new technologies mean that we were able to switch to a potential vaccine at an unprecedented rate. We were able to make the vaccine from scratch and bring it to the test in humans in just a few months - from the code to the candidate - which has never happened before with such a vaccine. If our approach works and the vaccine provides effective protection against diseases, this can fundamentally change our response to outbreaks of the disease in the future, " Researchers inform that at the first stage they will evaluate safety and search for the optimal dose of vaccine in 15 healthy volunteers aged 18-45 years. The first participant will receive a very low share of the vaccine, after which the team will increase it on the next volunteers. A second increased dose will be administered four weeks after the first. Scientists hope full-fledged vaccines will be ready by spring 2021. Recall that earlier in the United States announced successful trials of a vaccine against coronavirus.

Even a single dose of the drug can protect the body from COVID-19. The company plans to conduct the final stage of testing in July. It was also reported that four EU countries have concluded a contract for the purchase of vaccines from COVID. Germany, France, Italy and the Netherlands have signed an agreement with AstraZeneca to produce at least 300 million doses of a potential vaccine against coronavirus. News from Telegram. Subscribe to our channel https: // t. me / korrespondentnet Author: 1.